Dareen Alyousfi

Dr. Dareen Alyousfi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2026 in RSC Advances
Verified
Journal Article
Open access
AAAnes A. Al-Sharqi
Anes A. Al-Sharqi
MEMohammed E. Eissa
Mohammed E. Eissa
DADareen Alyousfi
Dareen Alyousfi
AAAhmed Eid Alharbi
Ahmed Eid Alharbi
IIIBRAHIM IBRAHIM
IBRAHIM IBRAHIM
Ahmed GhareebAhmed Ghareeb
Ahmed Ghareeb
Selenium–copper bimetallic nanoparticles (Se–Cu BMNPs) were synthesized using metabolic extracts from the marine bacterium Bacillus licheniformis LHG166 isolated from the Red Sea.

21 May 2025 in Lipids in Health and Disease
Verified
Journal Article
Open access
HDHussam Daghistani
Hussam Daghistani
GHGehan A. Hegazy
Gehan A. Hegazy
MAManal Alkhalofah
Manal Alkhalofah
AAAfaf Alsobeihy
Afaf Alsobeihy
SNSara Nasser
Sara Nasser
DADareen Alyousfi
Dareen Alyousfi
Long noncoding RNAs (lncRNAs) have emerged as critical regulators of lipid metabolism, playing pivotal roles in cholesterol biosynthesis, transport, and efflux. Familial Hypercholesterolemia (FH), a genetic disorder characterized by excessive low-density lipoprotein cholesterol (LDL-C) levels, remains a significant contributor to premature cardiovascular disease (CVD). Traditional diagnostic methods, including lipid profiling and genetic testing, have limitations in sensitivity and accessibility, highlighting the need for novel molecular biomarkers. This review delves into the mechanistic involvement of lncRNAs in FH pathogenesis, shedding light on their potential as non-invasive biomarkers and therapeutic targets. Key lncRNAs such as LeXis, CHROME, and H19 have been implicated in cholesterol regulation and atherosclerosis progression, making them attractive candidates for precision medicine applications. Additionally, advancements in AI-driven lncRNA discovery and single-cell transcriptomics are paving the way for innovative diagnostic and therapeutic strategies. Emerging RNA-based therapeutics, including antisense oligonucleotides, small interfering RNAs (siRNAs), and CRISPR-based gene-editing tools, hold promise for modulating lncRNA function to restore lipid homeostasis. However, challenges such as biomarker validation, efficient RNA delivery, and regulatory approval must be addressed for clinical translation. The integration of lncRNA-based approaches into FH management offers new possibilities for early detection, targeted therapy, and personalized cardiovascular risk assessment, underscoring the need for continued research in this rapidly evolving field.

24 April 2026 in RSC Advances
Verified
Journal Article
Open access
PDF file
IIIBRAHIM IBRAHIM
IBRAHIM IBRAHIM
HAHanadi A. Alahmadi
Hanadi A. Alahmadi
AAAnes A. Al-Sharqi
Anes A. Al-Sharqi
NZNidal Mohammed Zabermawi
Nidal Mohammed Zabermawi
MAMohammed Alsieni
Mohammed Alsieni
Ahmed GhareebAhmed Ghareeb
Ahmed Ghareeb
Biogenic TiO 2 –Zn nanocomposites from Red Sea Bacillus tequilensis MYG163 form an anatase–wurtzite heterojunction (8–15 nm) with antioxidant, anti-inflammatory, antimicrobial, antidiabetic, and hemocompatibility activities for multitarget therapy.

20 October 2026 in Genes
Verified
Journal Article
Open access
PDF file
BBBabajan Banaganapalli
Babajan Banaganapalli
WAWaad Fahad Alharbi
Waad Fahad Alharbi
WAWejdan Abdullah Alzahrani
Wejdan Abdullah Alzahrani
AEAshraf A. El-Harouni
Ashraf A. El-Harouni
MAMahmoud Almutadares
Mahmoud Almutadares
NSNoor Ahamd Shaik
Noor Ahamd Shaik
Background/Objectives: Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal tract. This study aimed to nominate candidate genes and pathways for IBD by integrating exome sequencing and gene expression data. Methods: Whole-exome sequencing (WES) was performed on 10 patients with Crohn’s disease (CD). Differential expression was analyzed with GEO2R in an independent RNA-seq dataset (GSE193677; 2490 biopsies from 1162 subjects). Immune-related differentially expressed genes (DEGs) were identified with ImmPort, hub genes by protein-protein interaction analysis, and enriched pathways with Enrichr. Missense variants were modeled with AlphaFold 3. Results: WES identified 484 genes with rare coding variants in all 10 patients, and 732 genes were differentially expressed in CD or ulcerative colitis, 234 of them immune-related. Network, pathway, and database filtering prioritized ATM, CSF1R, FN1, and IL11, which together carry eight rare missense variants, with in silico predictions ranging from tolerated to deleterious. Enriched pathways included cytokine and interleukin signaling, and structural modeling predicted conformational changes. Conclusions: ATM, CSF1R, FN1, and IL11 are candidate genes in immune-related pathways in IBD. Because the genomic and expression data came from different cohorts, these genes need replication and experimental validation.

30 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SASultan A. Alfawaz
Sultan A. Alfawaz
HAHaifa Almukadi
Haifa Almukadi
TSThoraia Shinawi
Thoraia Shinawi
DADalal Alfawaz
Dalal Alfawaz
DADareen Alyousfi
Dareen Alyousfi
BBBabajan Banaganapalli
Babajan Banaganapalli
Background/Objectives: Combining omics layers is widely expected to improve cancer drug response prediction, but this is rarely tested under family-wise error control or on an independent screen. We measured what somatic mutation and copy number data add to gene expression, and how well models transfer to unseen lineages and an external screen. Methods: We linked the Cancer Dependency Map transcriptomic, somatic mutation and copy number profiles to GDSC2 dose–response data for twelve mechanistically diverse anticancer compounds in 509 cell lines. Lineage-only, single-modality, early-fusion and stacked late-fusion gradient-boosting models were compared by repeated cross-validation (DeLong tests, Holm adjustment), leave-one-lineage-out transfer across eleven solid tumour histologies, and external validation on 77-163 held-out PRISM cell lines per compound. Results: Gene expression models outperformed tissue-of-origin baselines for all twelve agents (AUC 0.69–0.84; gains 0.024–0.169; Holm-adjusted p < 0.001 for seven drugs). Adding mutation and copy number data changed AUC by −0.015 to +0.035, and no per-drug gain survived multiplicity correction. Pooled across compounds, early fusion added 0.008 AUC (95% CI 0.000–0.016), a gain that fold-level re-analysis did not support. Mixed-lineage cross-validation exceeded leave-one-lineage-out AUC by a median of 0.030 (p = 0.0005). External PRISM AUCs ranged from 0.46 to 0.76 and followed the concordance between the two screens (Spearman rho = 0.72, p = 0.008). TreeSHAP attributions recovered known determinants, including SLFN11, TP53, BRAF, PIK3CA and downstream MAPK transcriptional effectors. Conclusions: In this twelve-drug panel, gene expression captured most of the predictable response variation. Accuracy fell on held-out lineages and on an independent screen, which sets empirical limits on how far these models can generalise.